Neuberger Berman Group
TXMD icon

Neuberger Berman Group’s TherapeuticsMD TXMD Stock Holding History

Neuberger Berman Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-375
Closed -$118K – 1754
2014
Q1 		$118K Buy
375
+86
+30% +$27.4K ﹤0.01% 1579
2013
Q4 		$75K Buy
+289
New +$63.3K ﹤0.01% 1592

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Neuberger Berman Group's TXMD Position: Q2 2014 in Review

Neuberger Berman Group sold out of TherapeuticsMD (TXMD) in Q2 2014, closing a stake of 375 shares — an estimated $118K sold.

Neuberger Berman Group first reported a position in TXMD in Q4 2013 and held it in 2 quarters. The position peaked at $118K in Q1 2014. 87 funds tracked by Wall St. Rank hold TXMD as of Q2 2014.

  • Neuberger Berman Group reported no remaining TherapeuticsMD position as of Q2 2014 after selling out during the quarter.
  • Neuberger Berman Group sold 375 TherapeuticsMD shares in Q2 2014, an estimated $118K.
  • Neuberger Berman Group first reported a position in TherapeuticsMD in Q4 2013 and held it in 2 quarters.
  • Neuberger Berman Group's TherapeuticsMD position peaked at $118K in Q1 2014.
  • 87 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2014.

Based on Neuberger Berman Group's 13F filing for Q2 2014, filed 5 Aug 2014.